|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial显示文摘 | Feng Du Zhaoxu Zheng SuSheng Shi Zhichao Jiang Tao Qu Xinhua Yuan Yongkun Sun Yan Song Lin Yang Jiuda Zhao Jinwan Wang Yihebali Chi | 2015 | Medicine2015，，23： | 1 |
| 2 | Treatment‐related adverse events of antibody‐drug conjugates in clinical trials:A systematic review and meta‐analysis显示文摘Background:The wide use of antibody‐drug conjugates(ADCs)is transforming the cancer‐treatment landscape.Understanding the treatment‐related adverse events(AEs)of ADCs is crucial for their clinical application.We conducted a meta‐analysis to analyze the profile and incidence of AEs related to ADC use in the treatment of solid tumors and hematological malignancies.Methods:We searched the PubMed,Embase,and Cochrane Library databases for articles published from January 2001 to October 2022.The overall profile and incidence of all‐grade and grade≥3 treatment‐related AEs were the primary outcomes of the analysis.Results:A total of 138 trials involving 15,473 patients were included in this study.The overall incidence of any‐grade treatment‐related AEs was 100.0%(95%confidence interval[CI]:99.9%–100.0%;I2=89%)and the incidence of grade≥3 treatment‐related AEs was 6.2%(95%CI:3.0%–12.4%;I2=99%).Conclusions:This study provides a comprehensive overview of AEs related to ADCs used for cancer treatment.ADC use resulted in a high incidence of any‐grade AEs but a low incidence of grade≥3 AEs.The AE profiles and incidence differed according to cancer type,ADC type,and ADC components. | Jinming Li Guoshuang Shen Zhen Liu Yaobang Liu Miaozhou Wang Fuxing Zhao Dengfeng Ren Qiqi Xie Zitao Li Zhilin Liu Yi Zhao Fei Ma Xinlan Liu Zhengbo Xu Jiuda Zhao | 2023 | Cancer Innovation2023，2，5： | 1 |
| 3 | Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis显示文摘Background:A high body mass index(BMI)can indicate overweight or obesity and is a crucial risk factor for breast cancer survivors.However,the association between high BMI and prognosis in early-stage breast cancer(EBC)remains unclear.We aimed to assess the effects of high BMI on the prognosis of patients with EBC.Methods:The PubMed,Embase,and Cochrane Library databases and proceedings of major oncological conferences related to the effects of BMI on the prognosis of breast cancer were searched up to November 2021.Fixedand random-effects models were used for meta-analyses.Pooled hazard ratios(HRs)and 95%confidence intervals(CIs)for disease-free survival(DFS)and overall survival(OS)were extracted from the included literature.Results:Twenty retrospective cohort studies with 33,836 patients with EBC were included.Overweight patients had worse DFS(HR:1.16,95%CI:1.05-1.27,P=0.002)and OS(HR:1.20;95%CI:1.09-1.33,P<0.001).Obesity also had adverse effects on DFS(HR:1.17,95%CI:1.07-1.29,P=0.001)and OS(HR:1.30,95%CI:1.17-1.45,P<0.001).Likewise,patients with high BMI had worse DFS(HR:1.16,95%CI:1.08-1.26,P<0.001)and OS(HR:1.25,95%CI:1.14-1.39,P<0.001).In subgroup analyses,overweight had adverse effects on DFS(HR:1.11,95%CI:1.04-1.18,P=0.001)and OS(HR:1.18,95%CI:1.11-1.26,P<0.001)in multivariate analyses,whereas the relationship that overweight had negative effects on DFS(HR:1.21,95%CI:0.99-1.48,P=0.058)and OS(HR:1.39,95%CI:0.92-2.10,P=0.123)was not statistically significant in univariate analysis.By contrast,obesity had adverse effects on DFS(HR:1.21,95%CI:1.06-1.38,P=0.004 and HR:1.14,95%CI:1.08-1.22,P<0.001)and OS(HR:1.33,95%CI:1.15-1.54,P<0.001 and HR:1.23,95%CI:1.15-1.31,P<0.001)in univariate and multivariate analyses,respectively.Conclusions:Compared with normal weight,increased body weight(overweight,obesity,and high BMI)led to worse DFS and OS in patients with EBC.Once validated,these results should be considered in the development of prevention programs. | Zhoujuan Li Guoshuang Shen Mingqiang Shi Yonghui Zheng Yumei Guan Yuanfang Xin Miaozhou Wang Fuxing Zhao Dengfeng Ren Jiuda Zhao | 2023 | Cancer Pathogenesis and Therapy2023，1，3： | 0 |
| 4 | Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer:A network meta-analysis显示文摘Background:Metastatic triple-negative breast cancer(mTNBC)is an aggressive histological subtype with poor prognosis.Several first-line treatments are currently available for mTNBC.This study conducted a network meta-analysis to compare these first-line regimens and to determine the regimen with the best efficacy.Methods:A systematic search of PubMed,EMBASE,the Cochrane Central Register of Controlled Bases,and mi-nutes of major conferences was performed.Progression-free survival(PFS),overall survival(OS),and objective response rate(ORR)were analyzed via network meta-analysis using the R software(R Core Team,Vienna,Austria).The efficacy of the treatment regimens was compared using hazard ratios and 95%confidence intervals.Results:A total of 29 randomized controlled trials involving 4607 patients were analyzed.The ranking was based on the surface under the cumulative ranking curve.Network meta-analysis results showed that cisplatin combined with nab-paclitaxel or paclitaxel was superior to docetaxel plus capecitabine in terms of PFS and ORR.For programmed death-ligand 1(PD-L1)and breast cancer susceptibility gene(BRCA)mutation-positive tumors,atezolizumab/pembrolizumab combined with nab-paclitaxel and talazoparib was superior to docetaxel plus capecitabine.No significant difference was observed among the treatments in Os.Neutropenia,diarrhea,and fatigue were common serious adverse events.Conclusion:Cisplatin combined with nab-paclitaxel or paclitaxel is the preferred first-line treatment for mTNBC.For PD-L1 and BRCA mutation-positive tumors,atezolizumab/pembrolizumab combined with nab-paclitaxel and talazoparib is an effective treatment option,Neutropenia,diarrhea,and fatigue are frequently occurring serious adverseevents. | Mingqiang Shi Zhoujuan Li Guoshuang Shen Tianzhuo Wang Jinming Li Miaozhou Wang Zhen Liu Fuxing Zhao Dengfeng Ren Jiuda Zhao | 2024 | Cancer Pathogenesis and Therapy2024，2，2： | 0 |
| 5 | Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort显示文摘Background On average,5-10%of patients are diagnosed with metastatic breast cancer(MBC)at the initial diagnosis.This study aimed to develop a nomogram to predict the overall survival(OS)in these patients.Methods The nomogram was based on a retrospective study of 9435 patients with de novo MBC from the Surveillance,Epidemiology,and End Results(SEER)database.The predictive accuracy and discriminative ability of the nomogram were determined using the concordance index(C-index),area under the time-dependent receiver operating characteristic curve(AUC),and calibration curve.Decision curve analysis(DCA)was employed to evaluate the benefits and advantages of our new predicting model over the 8th edition of the American Joint Committee on Cancer(AJCC)Tumor Node Metastasis(TNM)staging system.The results were validated in a retrospective study of 103 patients with de novo MBC from January 2013 to June 2022 at an institution in northwest China.Results Multivariate analysis of the primary cohort revealed that independent factors for survival were age at diagnosis,pathological type,histological grade,T stage,N stage,molecular subtype,bone metastasis,brain metastasis,liver metastasis,lung metastasis,surgery,chemotherapy,and radiotherapy.The nomogram achieved a C-index of 0.688(95%confidence interval[CI],0.682-0.694)in the training cohort and 0.875(95%CI,0.816-0.934)in the validation cohort.The AUC of the nomograms indicated good specificity and sensitivity in the training and validation cohorts,respectively.Calibration curves showed favorable consistency between the predicted and actual survival probabilities.Additionally,the DCA curve produced higher net gains than by the AJCC-TNM staging system.Finally,risk stratification can accurately identify groups of patients with de novo MBC at different risk levels.Conclusions The nomogram showed favorable predictive and discriminative abilities for OS in patients with de novo MBC.Other populations from different countries or prospective studies are needed to further validate the nomogram. | Lizhi Ning Yaobang Liu Yujin Hou Miaozhou Wang Mingqiang Shi Zhen Liu Jiuda Zhao Xinlan Liu | 2023 | Cancer Pathogenesis and Therapy2023，1，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员